The introduction of the tyrosine kinase inhibitor imatinib mesylate (Gleevec) has profoundly changed the treatment paradigm for patients with chronic myelogenous leukemia (CML).
Marcel Devetten, MD
Advertisement
Articles by Marcel Devetten, MD
Advertisement
Latest Updated Articles
- Refractory CML: Not All Forms of Resistance Are Equal
April 15th 2008
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies
2
FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC
3
Precision Medicine and the “Slow Death” of Transplant in Lymphoma
4
Unraveling Daraxonrasib’s Breakthrough in Metastatic Pancreatic Cancer
5